KUALA LUMPUR (Jan 23): Hamzarul Hazmir Hamdan has acquired 10 million shares or 9.52% in Practice Note 17 (PN17) entity Biosis Group Bhd, to become its second-largest shareholder.
In a filing to Bursa Malaysia today, personal care and pharmaceutical products manufacturer Biosis (fundamental:0; valuation: 0.3) said Hamzarul acquired the stake through an off-market transaction last Friday (Jan 16).
Following the acquisition, Hamzarul's stake had surpassed Lembaga Tabung Haji's (LTH) 8.69%, making LTH the third-largest shareholder in Biosis now.
Biosis' largest shareholder is Azizi Erwan, who owns 19.05% in the company. Biosis became a PN17 entity since June 2013.
Shares of Biosis has not been traded so far today. The stock's lastest closing price was 12 sen last Monday (Jan 19), for a market capitalisation of RM12.6 million.
(Note: The Edge Research's fundamental score reflects a company’s profitability and balance sheet strength, calculated based on historical numbers. The valuation score determines if a stock is attractively valued or not, also based on historical numbers. A score of 3 suggests strong fundamentals and attractive valuations.)